Clinical Trial

A Real-world Study to Compare the Effectiveness of Sacubitril/Valsartan Versus ACEi/ARB in HFrEF Patients

Completed
View on ClinicalTrials.gov →
Summary
This was a retrospective, observational, comparative cohort study using secondary data from electronic health records (EHR) from a local health unit that provides primary, secondary and tertiary care to a resident population in northern Portugal. The study aimed to assess the comparative effectiveness of sacubitril/valsartan (SAC/VAL) versus angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) in patients with heart failure with reduced ejection fraction (HFrEF).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-22.
Trial Details
NCT Number NCT07376265
Lead Sponsor Novartis Pharmaceuticals
Conditions Heart Failure
Enrollment 1,249 participants
Start Date 2023-10-20
Primary Completion 2024-04-11 (estimated)
Study Completion 2024-04-11 (estimated)
Updated on ClinicalTrials.gov 2026-02-04